"This webpage can include promotional content regarding one or several products of Terumo Europe, or some procedures concerning the use or implantation of such products. This webpage is exclusively intended for healthcare professionals and is in no event directed to the general public."

Cookie policy

This site uses cookies to improve your user experience. By using this website, you agree that we can place cookies on your device. For further information, please read our Privacy And Cookies Policy

I accept the terms and conditions
Skip Ribbon Commands
Skip to main content

News

 

 

New Data Demonstrate Clinical Safety and Efficacy of 3-Month DAPT after Ultimaster™ Sirolimus-Eluting Stent Implantationhttps://www.terumo-europe.com/en-emea/news/new-data-demonstrate-clinical-safety-and-efficacy-of-3-month-dapt-after-ultimaster™-sirolimus-eluting-stent-implantationNew Data Demonstrate Clinical Safety and Efficacy of 3-Month DAPT after Ultimaster™ Sirolimus-Eluting Stent ImplantationTOKYO, JAPAN 9/26/2019 10:00:00 PM<h3>​MODEL U-SES Study Presented at TCT 2019<br></h3>
Terumo Introduces New Radial to Peripheral (R2P™) Devices at TCT 2019https://www.terumo-europe.com/en-emea/news/terumo-introduces-new-radial-to-peripheral-(r2p™)-devices-at-tct-2019Terumo Introduces New Radial to Peripheral (R2P™) Devices at TCT 2019SAN FRANCISCO, USA9/25/2019 10:00:00 PM<h3>​Enables the Clinical, Economic, and Patient Benefits Associated with Radial Artery Access<br></h3>
Terumo to Increase Production Capacity for Alliance Businesshttps://www.terumo-europe.com/en-emea/news/terumo-to-increase-production-capacity-for-alliance-businessTerumo to Increase Production Capacity for Alliance BusinessTOKYO, JAPAN 9/19/2019 10:00:00 PM<p>​Capital Investment of 2 Billion Yen in Terumo Yamaguchi D&D for Pre-filled Syringes<br></p>
Terumo’s Pre-fillable Syringe PLAJEXTM Contributes to Providing Simple Administration Optionhttps://www.terumo-europe.com/en-emea/news/terumo’s-pre-fillable-syringe-plajextm-contributes-to-providing-simple-administration-optionTerumo’s Pre-fillable Syringe PLAJEXTM Contributes to Providing Simple Administration OptionTOKYO, JAPAN9/19/2019 10:00:00 PM<p>​Osteoporosis Treatment Formulation Developed by Asahi Kasei Pharma Receives Approval<br></p>
Terumo Invests 26 Million Euro in New Production Lines for its Belgian Facilityhttps://www.terumo-europe.com/en-emea/news/terumo-invests-26-million-euro-in-new-production-lines-for-its-belgian-facilityTerumo Invests 26 Million Euro in New Production Lines for its Belgian FacilityLeuven, Belgium7/7/2019 10:00:00 PM<p style="text-align:justify;">Terumo Corporation (TSE: 4543), a leading global medical device manufacturer, today announced an investment of 26 million euro in the production facility of Terumo Europe in Leuven (Belgium), where Terumo produces and assembles medical devices. Terumo extends its production capacity at Terumo Europe to meet the growing demand for Terumo products. The new production lines will be operational within two to three years. Terumo Europe employs approximately 1,300 people in the EMEA region.</p>